Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journ
Go back to Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journ| ULTRAGENYX PHARM (NASDAQ: RARE) | Delayed: 14.51 +0.01 (0.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.50 | 52 Week High | $117.12 | |||
| Open | $14.79 | 52 Week Low | $46.52 | |||
| Day High | $15.07 | P/E | N/A | |||
| Day Low | $14.07 | EPS | $-1.97 | |||
| Volume | 13,333,782 | |||||
